The role and research progress of cytoreductive nephrectomy in metastatic renal cell carcinoma
10.3969/j.issn.1006-5725.2025.13.002
- VernacularTitle:减瘤性肾切除术在转移性肾细胞癌治疗中的研究进展
- Author:
Cai-fang GUO
1
;
Hong FAN
1
;
Ting LUAN
1
;
Hui ZHAN
1
;
Haifeng WANG
1
;
Jiansong WANG
1
Author Information
1. 昆明医科大学第二附属医院泌尿外科,云南省泌尿外科研究所(云南 昆明 650101)
- Publication Type:Journal Article
- Keywords:
metastatic renal cell carcinoma;
cytoreductive nephrectomy;
targeted therapy;
immuno-therapy;
metastasectomy
- From:
The Journal of Practical Medicine
2025;41(13):1952-1957
- CountryChina
- Language:Chinese
-
Abstract:
The treatment landscape for metastatic renal cell carcinoma(mRCC)has evolved rapidly over the past two decades with the introduction of targeted therapies and novel immune checkpoint inhibitors.Among these developments,cytoreductive nephrectomy(CN)remains a controversial and unresolved issue,with its survival benefits being questioned compared to systemic therapy(ST).The role and optimal timing of CN in the context of modern systemic treatment for mRCC remain unclear.Additionally,there is still no well-defined consensus on patient selection for CN.Therefore,this article provides a concise review of current evidence regarding CN in mRCC,incor-porating the latest renal cancer management guidelines.We focus particularly on optimal surgical timing,candidate patient selection,and the therapeutic value of metastasectomy.Furthermore,we examine the current role of CN in metastatic non-clear cell renal cell carcinoma and explore its evolving clinical applications and future prospects in mRCC treatment.
